Tatia Chay Woodward

Tatia Chay Woodward is a seasoned executive in health economics and outcomes research, currently serving as Vice President of Value & Evidence Oncology HEOR Strategy at AbbVie since July 2024. Tatia previously held the position of Vice President at Pfizer, where leadership spanned global HTA, value evidence strategy, and innovative health economics methods. Earlier roles included senior positions at GSK, focusing on oncology value evidence outcomes, and at AstraZeneca, directing global health economics and payer analytics across immuno-oncology and hematology. Tatia's extensive experience is supported by advanced degrees in Public Health Genetics and Epidemiology from the University of Washington and The George Washington University, respectively, as well as an undergraduate degree in Biology from the University of Virginia.